Viela Bio is a clinical-stage biotechnology company advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease. 

TypeSubsidiary
Parent CompanyHorizon Therapeutics
HQGaithersburg, MD, US
Founded2018
Websitevielabio.com
Cybersecurity ratingAMore
Viela Bio was founded in 2018 and is headquartered in Gaithersburg, MD, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Viela Bio

Bing Yao

Bing Yao

Chairman and Chief Executive Officer
Mitchell Chan

Mitchell Chan

Chief Financial Officer
Edward Hu

Edward Hu

Director
Yanling Cao

Yanling Cao

Director
Jorn Drappa

Jorn Drappa

Chief Medical Officer, Head of Research and Development
Chris Nolet

Chris Nolet

Director
Show more

Viela Bio Office Locations

Viela Bio has offices in Gaithersburg and Rockville
Gaithersburg, MD, US (HQ)
1 Medimmune Way
Rockville, MD, US
2400 Research Blvd
Show all (2)

Viela Bio Financials and Metrics

Summary Metrics

Founding Date

2018

Total Funding

$325 m

Investors

In total, Viela Bio had raised $325 m. Viela Bio is a subsidiary of Horizon Therapeutics

Viela Bio Revenue

Viela Bio's revenue was reported to be $11.65 m in FY, 2020
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

50.0m11.7m

General and administrative expense

6.6m35.1m60.2m

R&D expense

42.4m104.6m103.3m

Operating expense total

192.3m139.7m163.5m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

General and administrative expense

10.2m15.3m14.4m

R&D expense

38.7m26.8m25.4m

Operating expense total

48.9m42.1m39.8m

EBIT

(48.9m)(42.1m)(39.8m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

126.9m200.9m130.1m

Accounts Receivable

30.0m5.4m

Prepaid Expenses

6.2m16.2m

Current Assets

139.4m351.0m389.3m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

189.0m155.7m163.6m131.6m

Accounts Receivable

5.0m5.1m

Prepaid Expenses

4.6m6.5m11.3m

Inventories

Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(190.3m)(86.4m)(150.7m)

Depreciation and Amortization

18.0k184.0k1.5m

Cash From Operating Activities

(29.5m)(105.0m)(106.1m)

Purchases of PP&E

(491.0k)(1.1m)(926.0k)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(159.5m)(26.4m)(74.9m)(40.8m)(79.6m)

Depreciation and Amortization

1.0k25.0k44.0k106.0k193.0k

Accounts Payable

(9.0m)

Cash From Operating Activities

(3.3m)(25.7m)(69.2m)(10.9m)(57.6m)
Show all financial metrics

Viela Bio Operating Metrics

Sep, 2019

Patent Applications (US)

13

Patents (US)

4

Patents and Patent Applications

113

Phase I Trials Products

6
Show all operating metrics

Viela Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Viela Bio Online and Social Media Presence

Embed Graph

Viela Bio News and Updates

Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others

Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio, ADC Therapeutics, Amgen, Morphosys and Xencor. Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies…

Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum

-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion-

Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today announced it will report its fourth …

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Viela Bio, Inc. - VIE

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Viela Bio, Inc. Buyout

WILMINGTON, Del., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Viela Bio, Inc. (“Viela”) (NASDAQ GS: VIE) regarding possible breaches of fiduciary duties and other violations of law related to Viela’s agreement to be acquired by Horizon Therapeutics plc …

UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion

Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the first quarter. "Adding Viela's research and clinical development capabilities along with its deep, mid-st…
Show more

Viela Bio Frequently Asked Questions

  • When was Viela Bio founded?

    Viela Bio was founded in 2018.

  • Who are Viela Bio key executives?

    Viela Bio's key executives are Bing Yao, Mitchell Chan and Edward Hu.

  • How many employees does Viela Bio have?

    Viela Bio has 95 employees.

  • What is Viela Bio revenue?

    Latest Viela Bio annual revenue is $11.7 m.

  • What is Viela Bio revenue per employee?

    Latest Viela Bio revenue per employee is $122.7 k.

  • Who are Viela Bio competitors?

    Competitors of Viela Bio include BIA Separations, Conagen and Genomatica.

  • Where is Viela Bio headquarters?

    Viela Bio headquarters is located at 1 Medimmune Way, Gaithersburg.

  • Where are Viela Bio offices?

    Viela Bio has offices in Gaithersburg and Rockville.

  • How many offices does Viela Bio have?

    Viela Bio has 2 offices.